Corrigendum to "Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis" [Radiother. Oncol. 187 (2023) 109839].

Autor: Kubeczko M; Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland. Electronic address: marcin.kubeczko@io.gliwice.pl., Jarząb M; Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland., Gabryś D; Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland., Krzywon A; Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland., Cortez AJ; Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland., Xu AJ; Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York City, USA.
Jazyk: angličtina
Zdroj: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 May; Vol. 194, pp. 110188. Date of Electronic Publication: 2024 Mar 06.
DOI: 10.1016/j.radonc.2024.110188
Databáze: MEDLINE
Externí odkaz: